ADMA Biologics (ADMA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on ADMA Biologics (ADMA) is Neutral.

The composite score behind that read is +0.08, weighing +0.22 of bullish evidence against -0.24 bearish.

ADMA Biologics last closed at $10.36, +0.29% on the session.

Against the IVW growth benchmark the position is -0.51% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

9 graded predictions for ADMA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks ADMA Biologics in the 63rd percentile on valuation and the 91st percentile on return on equity, where 100 is best.

ADMA Biologics is classified under Health Care / Biotechnology, with a market capitalisation of $2.31B.

StockMap tracks ADMA Biologics as the 77th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite ADMA Biologics ranks 46th of 381 in the group, against a group median of -0.08.